ProShare Advisors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

ProShare Advisors’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-27,690	Closed	-$667K	–	1958
2023 Q1	$667K	Buy	27,690 +12,362	+81%	+$155K	﹤0.01%	813
2022 Q4	$162K	Buy	15,328 +1,971	+15%	+$15.9K	﹤0.01%	1548
2022 Q3	$61K	Buy	13,357 +2,082	+18%	+$9.49K	﹤0.01%	1642
2022 Q2	$45K	Sell	11,275 -5,682	-34%	-$26.9K	﹤0.01%	1716
2022 Q1	$125K	Sell	16,957 -4,080	-19%	-$24.4K	﹤0.01%	1991
2021 Q4	$118K	Buy	21,037 +391	+2%	+$2.48K	﹤0.01%	2171
2021 Q3	$132K	Sell	20,646 -5,129	-20%	-$33K	﹤0.01%	1867
2021 Q2	$217K	Buy	25,775 +2,833	+12%	+$22.9K	﹤0.01%	2104
2021 Q1	$241K	Buy	22,942 +3,678	+19%	+$51.8K	﹤0.01%	1930
2020 Q4	$326K	Buy	+19,264	New	+$289K	﹤0.01%	1557

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

ProShare Advisors's PRVB Position: Q2 2023 in Review

ProShare Advisors sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 27,690 shares — an estimated $667K sold.

ProShare Advisors first reported a position in PRVB in Q4 2020 and held it in 10 quarters. The position peaked at $667K in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

ProShare Advisors reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
ProShare Advisors sold 27,690 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $667K.
ProShare Advisors first reported a position in Provention Bio, Inc. Common Stock in Q4 2020 and held it in 10 quarters.
ProShare Advisors's Provention Bio, Inc. Common Stock position peaked at $667K in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on ProShare Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.